Chronic Inflammation Explained: High-Yield MRCEM Primary Pathology Revision Notes and Practice Questions

Chronic inflammation sits at the intersection of basic science and acute clinical medicine in a way that makes it indispensable territory for MRCEM Primary pathology revision. The macrophage-driven tissue injury you see histologically in a granuloma is the same process generating the synovial destruction of a rheumatoid flare presenting to your resus bay, the mesenteric thickening in a Crohn’s exacerbation, or the vulnerable atherosclerotic plaque that has just ruptured to cause an STEMI. Understanding the cellular and molecular architecture of chronic inflammation is not an exercise in abstract biochemistry: it is the mechanistic explanation for why biologics work, why steroids suppress flares, and why untreated chronic disease generates irreversible organ damage. The MRCEM Primary SBA exam tests this material with specific, discriminating questions that reward candidates who understand mechanism rather than those who have merely memorised lists.

Definition, Clinical Context, and Why This Matters in the ED

Chronic inflammation is defined as a sustained, dysregulated inflammatory response lasting weeks to months or years, in which tissue injury and attempted repair occur simultaneously. It is not simply prolonged acute inflammation: the cellular cast, the mediator profile, and the structural consequences are qualitatively distinct. The conditions it underpins are commonplace in UK emergency departments. Inflammatory bowel disease affects approximately 300,000 people in the United Kingdom, with a significant proportion presenting acutely with flares to the ED. Gout, driven by monosodium urate crystal-induced chronic synovial inflammation, generates over 160,000 GP consultations annually. Atherosclerosis, fundamentally a chronic inflammatory disease of the arterial wall, is the substrate for the majority of acute coronary syndromes and strokes managed in UK emergency departments daily. For a rigorous overview of inflammatory disease burden in the UK context, the National Institute for Health and Care Excellence publishes guidelines across this spectrum of conditions that are directly relevant to emergency practice.

From an exam perspective, the RCEM curriculum for the MRCEM Primary explicitly covers pathological processes including inflammation, repair, and the cellular basis of disease. Questions may present a clinical vignette (a patient with a mediastinal biopsy showing non-caseating granulomas, or a histology report from a bowel resection specimen) and ask candidates to identify the cell type responsible, the cytokine driving the process, or the downstream consequence of a specific mediator. Precision at the cellular and molecular level is what separates high-scoring candidates.

Cellular Mechanisms of Chronic Inflammation

The Macrophage: Central Orchestrator

The macrophage is the dominant effector cell of chronic inflammation. Derived from circulating monocytes that extravasate into tissues in response to chemokines such as MCP-1 (CCL2), tissue macrophages undergo polarisation into functionally distinct phenotypes. Classical M1 activation, driven by IFN-gamma (from Th1 lymphocytes and NK cells) and LPS, produces a pro-inflammatory, microbicidal phenotype characterised by secretion of TNF-alpha, IL-1, IL-6, IL-12, reactive oxygen species, and proteases. This is the macrophage destroying tissue in active chronic inflammation. Alternative M2 activation, driven by IL-4 and IL-13 (from Th2 cells), produces an anti-inflammatory, pro-repair phenotype that secretes TGF-beta and VEGF, activates fibroblasts, and deposits collagen. M2 activation is the macrophage attempting to heal the wound, and when sustained, it produces pathological fibrosis.

The clinical implication is direct: anti-TNF biologics such as infliximab and adalimumab, which are used in Crohn’s disease and rheumatoid arthritis and whose side-effects present to the ED (opportunistic infections, infusion reactions), act precisely by neutralising the M1-derived TNF-alpha that sustains the chronic inflammatory loop. Understanding the cytokine being targeted explains both the therapeutic rationale and the mechanism of adverse effects.

Lymphocytes and Plasma Cells

CD4+ Th1 lymphocytes are essential amplifiers of macrophage-mediated chronic inflammation. Differentiated from naive T cells by IL-12 (itself secreted by activated M1 macrophages), Th1 cells secrete IFN-gamma, creating a self-amplifying feedforward loop. They are also the cells responsible for driving granuloma formation and sustaining cell-mediated immunity against intracellular pathogens.

CD4+ Th2 lymphocytes, differentiated by IL-4, drive a contrasting programme characterised by eosinophil recruitment (via IL-5 and eotaxin), IgE class switching in B cells, and mast cell sensitisation. This is the cellular basis of allergic and parasitic chronic inflammation, and it is mechanistically distinct from the Th1-driven granulomatous programme. Plasma cells, the terminally differentiated descendants of activated B cells, contribute to chronic inflammatory tissue damage through local immunoglobulin deposition, as exemplified by IgG-containing immune complexes in rheumatoid synovium and IgA nephropathy.

Eosinophils and Mast Cells

Eosinophils recruited to sites of chronic inflammation release major basic protein and eosinophil cationic protein, both of which cause direct epithelial and tissue injury. Their prominence in parasitic infection and allergic conditions (asthma, eosinophilic oesophagitis) is a reliable exam discriminator. Mast cells, tissue-resident and capable of activation via IgE receptor crosslinking or direct stimuli, link innate and adaptive responses through histamine, prostaglandin, leukotriene, and cytokine release.

Key Cytokine Mediators: A Focused Summary

TNF-alpha, secreted principally by macrophages and T cells, drives endothelial activation, leukocyte recruitment, fever, and cachexia, and promotes apoptosis of target cells. Its blockade by biologics is associated with reactivation of latent tuberculosis, which is a well-recognised and examinable complication. IL-1, also macrophage-derived, induces fever via prostaglandin E2 synthesis in the hypothalamic preoptic area, upregulates endothelial adhesion molecules, and drives hepatic acute phase protein synthesis. IL-6 is the primary stimulus for the hepatic acute phase response: it drives production of CRP, fibrinogen, serum amyloid A, and complement proteins while simultaneously suppressing albumin synthesis. IL-6 receptor blockade (tocilizumab) is an increasingly encountered therapeutic in the ED context, notably used in cytokine release syndrome. IFN-gamma is the defining Th1 cytokine, essential for classical macrophage activation and granuloma maintenance, and it upregulates MHC class II expression, enhancing antigen presentation. TGF-beta, secreted by M2 macrophages and regulatory T cells, is the principal pro-fibrotic cytokine, stimulating fibroblast proliferation and collagen synthesis. When TGF-beta signalling dominates the resolution phase, the result is irreversible scar tissue.

Granulomatous Inflammation: Structure, Causes, and Classification

Granulomatous inflammation is a morphologically distinct, specialised subtype of chronic inflammation. A granuloma is an organised aggregate of activated macrophages that have undergone transformation into epithelioid cells (so named because their abundant cytoplasm and indistinct cell borders resemble epithelium under light microscopy), often fused into multinucleate Langhans-type giant cells, surrounded by a cuff of CD4+ T lymphocytes. The formation of this structure requires sustained T-cell-derived IFN-gamma stimulation of macrophages and represents a mechanism for physically containing indigestible material or persistent intracellular pathogens.

The single most important taxonomic distinction for MRCEM Primary SBA revision is between caseating and non-caseating granulomas. Caseating granulomas, exhibiting central cheesy necrosis histologically, are essentially pathognomonic of Mycobacterium tuberculosis infection, though they also occur in histoplasmosis and occasionally other mycobacterial infections. Non-caseating granulomas encompass sarcoidosis, Crohn’s disease, primary biliary cholangitis, berylliosis, and foreign body reactions. This distinction consistently appears in question stems where the histology report is the discriminating clue.

For candidates using the MRCEM Primary revision course at EM Learning Centre, granulomatous disease sits within the pathology module and connects meaningfully to clinical scenarios encountered in anatomy teaching, including musculoskeletal manifestations of sarcoidosis relevant to joint and soft tissue anatomy in the limbs covered in lessons such as those on the hip joint, gluteal region, and compartments of the thigh.

Consequences of Chronic Inflammation: Tissue Remodelling and Systemic Effects

Chronic inflammation does not resolve cleanly. The balance between M1-driven injury and M2-driven repair, and between matrix metalloproteinase activity and TGF-beta-driven fibrogenesis, determines the structural outcome. In fibrosing conditions such as cryptogenic fibrosing alveolitis, primary biliary cholangitis, and the fibrosing phase of Crohn’s strictures, irreversible collagen deposition replaces functional parenchyma. Angiogenesis driven by VEGF sustains the chronically inflamed tissue by ensuring its vascular supply, but also contributes to the pannus formation seen in rheumatoid synovium and to tumour growth in the context of inflammation-associated carcinogenesis. The systemic effects of chronic, low-grade IL-6 and IL-1 secretion include the anaemia of chronic disease (reduced erythropoietin sensitivity and iron sequestration via hepcidin), the chronic elevation of CRP and fibrinogen that increases cardiovascular risk, and the constitutional symptoms (fatigue, weight loss, low-grade pyrexia) that bring patients to the ED. The BMJ has published extensively on the role of systemic inflammation as a cardiovascular risk modifier, content that contextualises the basic science within clinical practice.

How the MRCEM Primary SBA Exam Tests This Material

The MRCEM Primary exam tests basic sciences in clinical context. Stem formats you should anticipate for this topic include: a histology description accompanied by a photomicrograph description (epithelioid cells, Langhans giant cells, lymphocytic cuffing) with the question asking for the most likely diagnosis or the cell type responsible; a clinical vignette involving a patient on anti-TNF therapy presenting with constitutional symptoms and night sweats, asking for the most appropriate initial investigation; a question identifying which cytokine mediates fever in chronic inflammation (IL-1, via prostaglandin E2, not TNF-alpha directly); a question asking which cell predominates in the inflammatory infiltrate of established Crohn’s disease (macrophages and lymphocytes, not neutrophils); or a question distinguishing M1 from M2 macrophage function.

Common question traps include confusing the cellular predominance of acute versus chronic inflammation, conflating caseating and non-caseating granuloma aetiologies, attributing fever purely to TNF-alpha rather than recognising the prostaglandin E2 pathway downstream of IL-1, and failing to recognise that TGF-beta is anti-inflammatory in high concentrations while also driving fibrosis. RCEM curriculum mapping places this material under the Applied Pathophysiology domain, and candidates can review the current curriculum on the Royal College of Emergency Medicine website.

Revision Pearls: High-Yield Facts for MRCEM Primary Pathology Revision

1. EMPLE: Eosinophils, Macrophages (dominant), Plasma cells, Epithelioid cells, Lymphocytes. These are the cells of chronic inflammation. Neutrophils are not on this list.
2. Granuloma formation requires IFN-gamma from Th1 cells acting on macrophages. Without T-cell cooperation, granulomas do not form: this is why HIV-associated TB produces atypical, granuloma-poor histology.
3. Caseating equals TB until proven otherwise. Non-caseating encompasses sarcoidosis, Crohn’s, primary biliary cholangitis, and foreign body reactions.
4. IL-6 drives CRP via the hepatic acute phase response. In sepsis, a rapidly rising CRP reflects IL-6 activity. Anti-IL-6 therapy (tocilizumab) causes a striking fall in CRP that may mask ongoing infection.
5. TGF-beta is the fibrosis cytokine, secreted by M2 macrophages and regulatory T cells, activating fibroblasts to lay down collagen. It is also immunosuppressive in high concentrations.
6. Anti-TNF biologics reactivate latent TB because granuloma integrity depends on TNF-alpha for macrophage retention and activation. Latent TB screening before starting anti-TNF therapy is mandatory (NICE guideline TA375).
7. Eosinophil prominence in a chronic inflammatory infiltrate should direct thinking towards parasitic infection, allergic disease, or eosinophilic conditions, not mycobacterial or granulomatous disease.
8. M1 macrophages kill; M2 macrophages repair. M1 is activated by IFN-gamma and LPS. M2 by IL-4 and IL-13. M2 in excess produces fibrosis.

Common Pitfalls: Where Candidates Lose Marks

• Stating that neutrophils are the dominant cell in chronic inflammation. They are not: this is the single most commonly penalised error in pathology SBA questions on this topic.
• Confusing caseating and non-caseating granuloma aetiologies, particularly attributing non-caseating granulomas to TB.
• Attributing fever in chronic inflammation solely to TNF-alpha, rather than recognising that IL-1 induces fever via COX-2-mediated prostaglandin E2 synthesis in the hypothalamus.
• Failing to recognise that TGF-beta has a dual role: immunosuppressive at high concentrations, pro-fibrotic when acting on fibroblasts.
• Conflating Th1 and Th2 cytokine profiles. Th1 secretes IFN-gamma and drives macrophage activation and granuloma formation. Th2 secretes IL-4, IL-5, IL-13 and drives eosinophilia and IgE responses.
• Overlooking that VEGF, although classically associated with tumour angiogenesis, is also a macrophage product sustaining the chronic inflammatory microenvironment.

How EM Learning Centre Supports Your MRCEM Primary Revision

MRCEM Primary pathology revision demands a structured, high-yield approach that links basic science to clinical scenarios without sacrificing mechanistic depth. The EM Learning Centre provides exactly this. Our MRCEM Primary course delivers curriculum-mapped lessons across pathology, physiology, pharmacology, anatomy, and microbiology, each written at registrar level and paired with SBA practice questions that mirror the format and difficulty of the actual exam. Anatomy content, including the hip joint and gluteal region, the compartments of the thigh, and the popliteal fossa and knee, is taught with direct links to pathological processes including inflammatory arthropathy, compartment syndrome, and soft tissue infection, reinforcing the basic-science-to-clinical-presentation learning model that the MRCEM Primary rewards.

If you are building your revision plan and want structured access to high-quality SBA practice questions, worked explanations, and curriculum-aligned teaching, the MRCEM Primary revision course at EM Learning Centre is designed specifically for UK emergency medicine trainees at every stage of preparation. Consistent, evidence-based revision built on mechanistic understanding is the most reliable route to a pass.

References

1. Royal College of Emergency Medicine. MRCEM curriculum and assessment framework. rcem.ac.uk
2. National Institute for Health and Care Excellence. Overview of inflammatory and autoimmune conditions. nice.org.uk
3. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis (TA375 and associated guidance). nice.org.uk
4. The BMJ. Inflammation and cardiovascular disease: mechanisms and clinical implications. bmj.com
5. NHS. Inflammatory bowel disease overview. nhs.uk